Advertisement: partnersand mid banner
Advertisement: Kao Data Centre mid banner
ARM Innovation Hub
Advertisement: RSM mid banner
Advertisement: Mogrify mid banner
Advertisement mid banner S-Tech 1
Advertisement: SATAVIA mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Cambridgeand mid banner advertisement
Advertisement: EBCam mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: CJBS mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Cambridge Network mid banner
12 May, 2022 - 11:38 By Tony Quested

Avacta therapeutics arm quits Cambridge

UK life science company Avacta is closing its therapeutics facility in Cambridge and will now house all relevant staff under one roof in London.

The company declined to say how many staff were employed at Cambridge or how many had agreed to transfer to the new therapeutics HQ at Scale Space in Imperial College’s White City Campus. Previously the therapeutics Research & Development teams were split between Cambridge and London.

A spokesperson told Business Weekly that the new site was “better equipped to serve the development of both Avacta and its people – the key benefits behind the decision being that the site is larger and houses more modern facilities.”

The AIM-listed group is nevertheless going against the flow of traffic. It moves out of Cambridge, one of the world’s most prestigious life science clusters, just as record numbers based here expand facilities and newcomers flow in.

Avacta said the new therapeutics HQ – it runs diagnostics from separate facilities – is designed to support the continued growth of the company’s pre-clinical and clinical development pipelines of innovative cancer therapies. 

The move follows the transition of AVA6000, the lead pre|CISIONTM targeted chemotherapy programme and a tumour activated form of doxorubicin, into the clinic in August 2021.

Dr Fiona McLaughlin, chief scientific officer at Avacta, said: “This move is the result of a clear vision to bring together the research and development teams into one hub to facilitate the translation of our in-house research from bench to bedside. 

“We are now at the heart of the innovative White City community in London, readily accessible to our collaborators around the world and poised to take Avacta to the next level in its evolution as a clinical stage biopharmaceutical company.”

Newsletter Subscription

Stay informed of the latest news and features